Natco Pharma Ltd, Winner of 'Golden Peacock Innovation Management Award' for the year 2015
Natco Pharma Ltd has informed BSE regarding a Press Release dated October 12, 2015 titled "Natco Pharma Ltd, Winner of 'Golden Peacock Innovation Management Award' for the year 2015". Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, 2011
Natco Pharma Ltd has submitted the disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, 2011 Shareholding Pattern For September 30, 2015
Natco Pharma Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015. Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Venkata Satya Swathi K has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Rajeev Nannapannei has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Natco frets over delay in multiple sclerosis drugs US launch
The delay in getting regulatory approvals and launching it in a 20 milligram dose in that key market has dashed those hopes. Disclosure of Voting results of AGM (Clause 35A)
Natco Pharma Ltd has informed BSE regarding the details of Voting results at the Annual General Meeting (AGM) of the Company held on September 26, 2015, under Clause 35A of Listing Agreement. Outcome of AGM
Natco Pharma Ltd has informed BSE that the Annual General Meeting (AGM) of the Company was held on September 26, 2015. Outcome of QIP Committee Meeting
Natco Pharma Ltd has informed BSE that Committee of Directors for QIP of the Company at its meeting held on September 18, 2015, approved the issue and allotment of 1600000 Equity Shares of face value Rs. 10/- each to eligible Qualified Institutional Buyers (QIB) at the issue price of Rs. 2130.55 per Equity Share, aggregating to Rs. 3,408.88 millions.Further, the Paid-up Capital of the Company increased from Rs. 33,23,48,490/- to Rs. 34,83,48,490/-. Outcome of Committee Meeting
Natco Pharma Ltd has informed BSE that in respect of the QIP, the Committee of Directors (the "Committee") of the Company has at its meeting held on September 15, 2015, inter alia, approved the following:1. Issue Price of Rs. 2,130.55, after giving discount of upto 5% i.e Rs. 112.13 per Equity Share, to the Floor Price of Rs. 2,242.68 per Equity Share as per the SEBI ICDR Regulations and shareholders' approval, for the Equity Shares to be...